

REMARKS

Currently claims **1 through 44** are pending. Claims **3, 4, 7, 8, 9, 11, 13, 15, 16, 17, 19, 20, 21, 22, 23, 30 and 31** have been amended in order to reduce the filing fee by removing multiple dependencies and/or to correct typographical errors.


The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:



Frank P. Grassler
Attorney for Applicants
Reg. No. 31,164

Date: July 28, 2006
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988

Application No. PCT/EP2005/000841
Attorney Docket No. PLP573

Amendments to the Abstract:

Please substitute the attached Abstract, which has been placed on a separate sheet of paper according to US practice, as required under 37 CFR 1.72(b).